This may have repercussions on the efficacy results, since in almost all clinical practice series presented to date for the different biologic drugs, but mainly anti-IL23 and anti-IL17, the response is initially better when the patient has not failed successively to different drugs for the treatment of their moderate–severe psoriasis [16,17]. Here, IL17A is linked to psoriasis.